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The master regulator of the macrophage development, differentiation, 
proliferation, survival, phagocytosis, cytokine secretion, motility, adhesion, 
migration, and spreading is the receptor tyrosine kinase (RTK) colony stimulating 
factor-1 receptor (CSF-1R). Aberrant CSF-1R signaling is present amongst a 
variety of highly prevalent and devastating human diseases in the United States 
such as atherosclerosis, cancer, inflammatory bowel disease, arthritis, and 
neuro-demyelination/neuro-degeneration. A better understanding of basic 
mechanisms that govern macrophage development and function is of vital 
importance in treating patients afflicted with these conditions/diseases. CSF-1R 
presentation on the macrophage cell surface is a required precursor for CSF1-
induced RTK dimerization (activation) and downstream CSF-1R signaling 
cascades. Mechanisms which regulate CSF-1R trafficking are unstudied and 
mechanisms of RTK trafficking regulation are poorly understood. The 
evolutionarily conserved C-terminal Eps15 Homology Domain (EHD) protein 
family consists of vesicular trafficking regulating proteins. However, the role of 
EHD proteins in CSF-1R trafficking and signaling has not been studied. I have 
utilized primary (non-immortalized) murine/mammalian macrophages under 
 
 
inducible Ehd1 gene deletion/knockout (EHD1-KO) to explore the role of EHD1 in 
CSF-1R trafficking in macrophages. I have discovered an entirely novel function 
for EHD1 in anterograde transport and presentation of CSF-1R on the 
macrophage cell surface. EHD1-KO macrophages have significantly depleted 
total and surface CSF-1R expression (i.e. receptor available for ligand-binding 
and subsequently CSF-1R activation/signaling) when compared with control 
macrophages. In EHD1-KO macrophages, newly synthesized CSF-1R en route 
to the cell surface is essentially shunted to the lysosome and degraded. These 
findings reveal an entirely novel and essential role for EHD1 in anterograde 
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The monocyte/macrophage cell lineage  
Cells of the monocyte/macrophage lineage play fundamental roles in 
integrating the two major arms (innate and adaptive) immune system. Colony-
stimulating factor-1 receptor (CSF-1R) signaling is essential for the development 
of the cells of the monocyte-macrophage lineage by mediating the proliferation 
and differentiation of myeloid progenitors into mature, fully functional 
macrophages (1). CSF-1R signaling has been demonstrated to instruct 
hematopoietic stem cells (HSCs) to differentiate into macrophages via myeloid-
lineage transcription factor PU.1, providing a mechanism for the immune system 
to increase macrophage numbers during infection/inflammation (2). 
Abnormalities in the development of this cell lineage are incompatible with an 
efficient and healthy immune system (3–5).  
Macrophages also play pivotal roles in wound repair and the removal of 
apoptotic cells. Phagocytosis and subsequent removal of necrotic tissues by 
macrophages is an important part of normal human physiology.  In wound repair, 
macrophages function in the production of the new extracellular matrix. The 
mechanism by which macrophages help produce this extracellular matrix is via 
macrophage arginase which allows the conversion of arginine to ornithine. This 
conversion is necessary to make collagen—an essential building block for 
reconstruction of damaged tissues (6).  
 
Of clinical relevance, macrophages are also known to be present in 
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common in human diseases (Figure 1.1). More specifically, macrophages are 
known to be involved in immunological diseases (7–9) such as rheumatoid 
arthritis, inflammatory bowel disease, and demyelinating neurological diseases 
(10–12). Additionally, macrophages also play key homeostatic roles in non-
immune diseases such as atherosclerosis and cancer (13–15).  
In the context of cancer, macrophages are key players in 
regulating/maintaining the tumor microenvironment and are known as Tumor-
Associated Macrophages (TAMΦ). TAMΦs take part in a positive feedback loop 
involving tumor cells. Briefly, the tumor cells secrete CSF-1, which attracts and 
maintains TAMΦs along with a combination of other growth factors. TAMΦs in 
return secrete Epidermal Growth Factor (EGF) and Vascular Endothelial Growth 
Factor (VEGF) which promotes survival of the tumor cells. Specifically, EGF 
promotes the growth of the tumor directly, and VEGF promotes vascularization of 
the neoplastic tissue (16).  
Given their relatively short life span yet relatively constant numbers in 
circulation and tissues under homeostasis, and a rapid and sometimes marked 
increase in numbers in the face of infection or inflammation, macrophages need 
to be continuously produced to match the body’s needs. CSF-1R signaling is 
essential for this process to occur (17). It is also known that critical proliferative 
signals generated by CSF-1R occur when the receptor has been internalized and 
is in the endocytic recycling compartment (18). However, mechanisms which 
regulate CSF-1R trafficking have not been studied. A better understanding of 
basic mechanisms that govern macrophage biology/CSF-1R signaling is of vital 
4 
 
importance regarding treatment of patients afflicted with these conditions. 
CSF-1R as the master regulator of macrophages 
CSF-1R signaling that is essential for appropriate macrophage 
development and population maintenance (Figures 1.2 and 1.3) is controlled by 
binding and subsequent activation of the receptor by CSF-1. CSF1-induced CSF-
1R signaling has also been shown directly to regulate the physiological functions 
of macrophages such as proliferation, differentiation, spreading, migration, 
phagocytosis, and cytokine secretion (Figure 1.4). Furthermore, CSF-1R 
signaling also controls universal transcription of the macrophage genome and 
subsequent protein expression (19). Hence, if CSF-1R does not directly regulate 
macrophage function, the receptor indirectly regulates macrophage biology due 
regulation of cellular protein expression (Table 1.1).  
CSF-1R, like all receptor tyrosine kinases (RTKs), is synthesized in the 
endoplasmic reticulum, glycosylated/matured in the Golgi apparatus, and then 
transported to the cell surface where it can become activated via binding of 
ligand (CSF-1). Transport of newly synthesized receptor is a prerequisite step in 
RTK/CSF-1R activation and signaling (20). Furthermore, if CSF-1R does not 
make it to the cell surface or is not oriented on the plasma membrane correctly, it 
cannot bind ligand and become activated (signal).  
Similarly, to other RTKs, ligand binding of CSF-1 (M-CSF) or IL-34 
activates CSF-1R by inducing conformational changes, dimerization, and trans-
phosphorylation, leading to the association of key cytoplasmic signaling 
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intermediates.  Signal transduction cascades are activated, including the PI3-
kinase/AKT, Ras/Erk, and Rho/Rac pathways (21, 22). Transcription occurs 
downstream of these signaling pathways dictating changes in macrophage 
biology. 
When CSF-1 binding of CSF-1R occurs at the macrophage’s surface 
(RTK activation) endocytic internalization of CSF-1R occurs (18, 23). 
Endocytosed RTKs are targeted to the lysosome, which our laboratory and 
others have demonstrated to be dependent on CBL-family proteins and ESCRT 
complexes (20, 24–26). Also, ligand-stimulated and internalized RTKs can transit 
through an endocytic recycling pathway (27). These alternate fates of 
internalized RTKs are of a high biological interest as their balance determines the 
magnitude and duration of signaling in response to ligand-induced stimulation 
(28). Furthermore, activated RTKs continue to signal in endosomes and indeed 
may require endocytosis to transduce specific signals (20). CSF-1R signaling at 
the cell surface is known to induce phosphorylation of the STAT3 pathway 
specifically and not the Erk and Akt pathways. However, once internalized, CSF-
1R signaling from the endosome results in phosphorylation of the Erk and Akt 
pathways (18).  
After newly synthesized receptor has been transported to the cell surface, 
it will undergo constitutive recycling if CSF-1 activation does not occur. CSF-1R 
is known to undergo constitutive recycling at a rate of 4 molecules/cell/s at 
steady state (29). The combinatory effects of the rate of receptor internalization, 
constitutive recycling, and degradation determine the half-life (t1/2) of an RTK. 
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CSF-1R has one of the fastest turnover rates ( t1/2 < 1 hour) of any known RTK 
(25). Trafficking of CSF-1R happens extremely fast. In contrast, EGFR has one 
of the slowest turnover rates (t1/2 > 24 hours). The rapid turnover rate of CSF-1R, 
as compared to other RTKS, is an important caveat which must be taken into 
account when trying to understand the biology of the receptor. 
C-terminal Eps15 Homology Domain (EHD) containing proteins 
The four members of C-terminal Eps15-homology domain-containing 
(EHD) protein family have emerged recently emerged as regulators of endocytic 
traffic of cell surface receptors (30). EHD proteins are characterized by highly 
related primary amino acid sequences amongst family members and similar 
domain structure. The domains are composed of a nucleotide-binding G-domain, 
coiled-coiled regions that form a membrane lipid-binding domain, an EH domain 
(67-86% homology, Figure 1.5A), and a C-terminus that mediates interactions 
with partner proteins by binding to asparagine-proline-phenylalanine (NPF)-
containing motifs (Figure 1.5B). In vitro studies have suggested EHD proteins 
function in a manner similar to the protein dynamin—as scission proteins to 
promote vesicular budding and membrane tubulation (Figure 1.5C). Furthermore, 
EHD1 has been linked to the cellular endocytic recycling compartment (Figure 
1.6). These studies have shown EHD proteins to be involved in the recycling of 
immune-relevant receptors such as MHC class I, MHC class II, β1 integrins (30). 
Furthermore, EHD proteins have been correlated with various human diseases 
(Table 1.2). However, the role of EHD proteins in CSF-1R trafficking and 
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signaling has not been studied. 
Mouse models to study EHD proteins  
Our laboratory has previously used individual and combined gene deletion 
approaches in mice to discover physiological roles of EHD proteins in vivo. EHD1 
deletion on a mixed C57BL/6 and 129Sv background is partially embryonic lethal 
and associated with defective spermatogenesis and lens developmental defects. 
EHD1 deletion is fully embryonic lethal on a predominantly C57BL/6 background 
and related to defective neural tube closure due to lack of ciliogenesis and 
altered Hedgehog signaling (31–33). EHD1-null mice also exhibit a skeletal 
myopathy (34, 35). EHD4-null mice exhibit reduced testes size and male fertility 
while EHD3-null mice are normal (36); however, EHD3/EHD4-null mice show 
high early neonatal lethality and develop rapidly progressive renal thrombotic 
microangiopathy (37). Further analyses of EHD3-null mice have revealed a 
pivotal role of EHD3 in regulating cardiac membrane excitability and rhythm (38). 
Consistent with these physiological functions, EHD proteins have been found to 
regulate trafficking to the cell surface of non-RTK receptors, such as 
Sodium/Calcium (Ca2+) exchanger L-type Ca2+ channel type 1.2 (39) and 
voltage-gated T-type Ca2+channels CaV3.1, and CaV3.2 (40) in cardiomyocytes, 
and feeling protein Fer1L1 in skeletal muscle cells (34, 35). Currently, little is 
known about the physiological roles of EHD proteins. EHD-regulated endocytic 
traffic of other receptors characterized in cellular models, including transferrin 
receptor (41), MHC class I (42), β1 integrin (43), cadherin 23 (44), L1/Ng-CAM 
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(45), and surface protease BACE1 (46). Similarly, the functional importance of 
EHD1 and EHD4 localization to the neuromuscular junction (47) remains unclear. 
In contrast to non-RTK receptors, less is known about the roles of EHD 
proteins in RTK traffic. EHD4 expression was found to be upregulated by 
neurotrophin stimulation of neuronal cultures, and knockdown studies showed 
that EHD4 was required for the post-stimulation retrograde traffic of neurotrophin 
receptor TrkA (48). We have observed an increased cytoplasmic and reduced 
surface localization of vascular growth factor receptor 2 (VEGF2) in glomerular 
endothelial cells of EHD3/EHD4 double knockout mice with a glomerular disease, 
suggesting a potential role of EHD proteins in facilitating the surface mobilization 
of RTKs. At present, no role of EHD proteins in CSF-1R traffic or monocyte-
macrophage function is known. 
To establish a biological system in which the functions of endocytic 
recycling can be examined in vivo as well as ex vivo, our laboratory has focused 
on four highly conserved proteins of the Eps15-homology domain-containing 
(EHD) protein family. By creating constitutive as well as inducible mouse 
knockout (KO) models, our laboratory aims to uncover previously unanticipated 
roles of these proteins in physiological processes. To elucidate the roles of EHD 
protein-dependent endocytic recycling in the macrophages, I initiated studies 
using mouse macrophages, given the critical duties of the endocytic machinery in 
basic macrophage biology, including phagocytosis, endocytic internalization of 
foreign antigens or antigen/antibody complexes, antigen processing and display 
on the surface, and other roles (49, 50). Mutations of endocytic regulatory 
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proteins in genetic immune disorders, such as Chediak-Higashi Syndrome (51) 
and familial lymphohistiocytosis (52) significantly affect macrophage function. 
Hypothesis 
I hypothesize that EHD1 orchestrates optimal CSF-1R expression and 
signaling in macrophages. Furthermore, EHD1 regulates macrophage CSF-1R 
surface expression via control of CSF-1R transport to the cell surface, thus 
permitting stabilization of the dimerized form of the receptor by CSF-1 
(activation). This hypothesis will be explored using primary murine bone marrow-
derived macrophages (BMDMs) from constitutive and inducible EHD knockout 
mice. Using an array of biochemistry, immunofluorescence, and Fluorescence 
Activated Cell Sorting (FACS) analysis, I will characterize the physiological 
functions of EHD1 in the context of CSF-1R signaling in macrophages 
responses. Furthermore, I will seek to describe a mechanism behind any 























Table 1.1. Modulation of protein expression by CSF-1. CSF-1 up-regulates 
human monocyte expression of the P2X7 extracellular ATP receptor that 
regulates DCs and macrophage inflammatory functions, including intracellular 
bacterial killing, and favors the generation of cytokines that stimulate T helper 2 
responses. Independently of LPS, CSF-1 induces monocytes to express a variety 
of cytokines and immunologically relevant cell surface molecules. 










Table 1.2. Relationship of EHD proteins to human disease. The table 
highlights known correlation between EHD proteins and human diseases using 
fold increase or decrease of the corresponding EHD protein to a given human 
disease. 






































Figure 1.1. Macrophages in human disease. Involvement of CSF1-regulated 
mononuclear phagocytes in immunity and inflammation. By regulating the 
development and activation of mononuclear phagocytes, CSF-1 contributes to 
immunity to viral, bacterial and fungal infections and increases the efficiency of 
vaccination (e.g. Sendai virus and glioma vaccines). The involvement of specific 
macrophage populations is shown. CSF-1 is also involved in promoting and 
sustaining inflammation in several diseases (e.g. Alzheimer’s disease, systemic 
lupus erythematosus, arthritis and obesity) and in the regulation of TAMΦs in 
enhancing tumor progression and metastasis (not shown). Although most studies 
have been performed in rodents, for illustrative purposes this information is 
depicted on a human body.  












Figure 1.2. The origins of tissue macrophages. Developmental origin of tissue 
macrophages in the mononuclear phagocyte system. Embryonic macrophages 
from the yolk sac and fetal liver self-renew in homeostatic conditions and are 
driven by M-CSF (CSF-1) or GM-CSF. Inflammatory macrophages of embryonic 
origin also self-renew. 














Figure 1.3. Model of how CSF-1R controls macrophage tissue density. CSF-
1R signaling controls the proliferation of tissue macrophages. Constant secretion 
of CSF-1 by tissue stroma and consumption by macrophages maintains 
population density just below the CSF-1R signaling threshold required for 
proliferation (A). Steady state death/ migration (B) or disappearance during 
inflammation (C) increases available CSF-1 without necessarily changing 
production of CSF-1, thereby allowing proliferation to restore normal density. 
Elevated CSF-1 secretion stimulates cells to proliferate to higher tissue density 
than normal (D), but can also stimulate monocyte recruitment via macrophage 
chemokine production (E). Recruitment likely requires a higher threshold of CSF-
1R signaling than proliferation, but this remains to be established. Other factors, 
such as IL-4, can allow macrophages to proliferate independently of CSF-1 
thereby increasing macrophage numbers when CSF-1 is limiting and without a 
concurrent increase in monocyte recruitment (F).  












Figure 1.4. CSF-1R signaling governs macrophage biology. Signaling 
pathways regulated by colony-stimulating factor-1 receptor (CSF-1R) in myeloid 
cells. Binding of Colony-stimulating factor-1 (CSF-1) stabilizes a dimeric form of 
the CSF-1R and leads to activation of the CSF-1R kinase, its tyrosine 
phosphorylation, and the direct association of signaling molecules with the 
receptor through their phosphotyrosine-binding domains. The precise 
involvement of the Ras–MEK–MAPK pathway in the CSF1-regulated proliferation 
and differentiation of myeloid cells is not clear, but Raf-1 seems to signal 
independently of this pathway. Differences in signaling pathways are also 
expected to exist between macrophage progenitor cells and macrophages. 




Figure 1.5. C-terminal Eps15 homology domain (EHD) proteins. 
 
  



























Figure 1.5. Domain architecture, conservation, and function of C-terminal 
Eps15 homology domain (EHD) proteins. (A) The EHD proteins, comprised of 
534–543 amino acids, each contain two helical regions, a conserved ATP-
binding domain, a linker region and an EH domain localized to the C-terminus of 
the protein. (B) Comparison of the amino acid sequence identity of full-length 
EHD proteins. (C) Proposed model of EHD protein function. Cytoplasmic 
localized EHD proteins bind ATP and dimerize. EHD dimerization causes the 
formation of a membrane binding site and the EHD proteins associate with 
tubular membranes, where they undergo further oligomerization. Upon ATP 
hydrolysis, the membranes are destabilized, leading to scission of vesicles 
containing concentrated cargo/receptors, thus facilitating vesicular transport. 









Figure 1.6. Regulation of endocytic transport by EHD proteins. Internalized 
receptors reach the sorting or early endosome (EE) and are trafficked through 
one of at least four pathways. Receptors slated for degradation are sorted to EE 
microdomains containing EHD4, Rab5, and Rabenosyn-5 and transported to late 
endosomes and lysosomes. Other internalized proteins, such as the Shiga toxin, 
are carried from EE to the Golgi via an EHD3 and/or EHD1-dependent retrograde 
pathway. Receptors that recycle back to the plasma membrane can do so 
directly from EE in a poorly defined manner that requires the function of Rab4 
(fast recycling). Alternatively, many receptors are first directed to the perinuclear 
endocytic recycling compartment and then shuttled to the plasma membrane 
(slow recycling). Slow recycling requires the following function of multiple 
regulators including Rab5, Rab11, Rab8a, their effectors (Rabenosyn-5, Rab11-
FIP2, and MICAL-L1, respectively), and EHD proteins. 
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Bovine Serum Albumin (cat. # A7906-100G), Paraformaldehyde (cat. # 
158127-500G), Triton X-100 (cat. # 93418), and 4-hydroxytamoxifen (cat. # 
T176-10MG) were from Sigma-Aldrich (St. Louis, MO). Propidium Iodide staining 
solution (cat. # 00-6990-42) was from eBiosciences. Hema staining solutions 
(cat. # 23-123919) were from Fisher. 3H-thymidine (cat. # 2407001, 2.0Ci/mmol) 
was from MP Biomedical and [35S] (cat. # NEG772007MC, 1175 Ci/mmol) was 
from Perkin Elmer. Bafilomycin A1 (cat. # 196000) was from MilliPore. EDTA-free 
protease inhibitor cocktail (cat. # 4693159001) was from Roche, ECL 
development reagent (cat. # 32106) was from Thermo-Scientific. Recombinant 
CSF-1 (catalog # 315-02) was from Peprotech (Rocky Hill, NJ). CFSE (cat. # 
C34554) and RPMI-1640 (cat. # SH30027.02) were from ThermoFisher 
Scientific. Penicillin/streptomycin (cat. # 15140-122) and Fetal Bovine Serum 
(cat. # 10427-028; lot # 1662765A120-01) were from Life Technologies. 
Antibodies: Brilliant Violet 711 conjugated anti-CSF-1R and anti-CSF-1R, AFS98 
(cat. # 135515) were from Biolegend; anti-CSF-1R C-20 (cat. # sc-692), anti-
CSF-1R G-17 (cat. # sc-31638) anti-HSC70 (cat. #sc-7298), and anti-LAMP1 
1D4B (cat. # sc-19992) were from Santa Cruz Biotechnology; anti-EHD1 (cat. # 
ab109311) was from Abcam; anti-β-Actin (cat. # A5316) was from Sigma-Aldrich; 
anti-pErk42/44 (cat. # 9101) was from Cell Signaling Technology; F4/80-APC, 
BM8 (cat. # 17-4801-82) and anti-GM130 (cat. # 610822) were from BD 
Biosciences; CD16/32 (cat. # 14-0161), and APC-conjugated anti-Annexin V (cat. 
# 17-8007-72) were from eBiosciences; a polyclonal rabbit antibody recognizing 
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EHD1 and EHD4 was generated in-house was described previously (45). 
Secondary fluorochrome-conjugated antibodies were from Life Technologies. 
Mouse Models 
Ehd1-null mice were maintained on mixed 129; B6 background (36). 
Single nucleotide polymorphism (SNP) analysis (DartMouse, Lebanon, NH) 
revealed these to have ~70% contribution from the C57Bl/6 genome (Figure 2.1). 
Ehd1-WT (wild type), Ehd1-het (heterozygous), and Ehd1-null (homozygous null) 
mice were generated by mating Ehd1-het mice. Mice used in this study are 
named according to Table 2.1.  Breeders were maintained on high-fat chow (# 
2019, Harlan Laboratories Inc., Madison, WI). Genomic DNA was extracted from 
embryonic yolk sacs or adult tail tips with proteinase K digestion, isopropanol 
precipitation and used for genotyping as described previously (Rainey et al., 
2010).   
To conditionally delete Ehd1, Ehd1flox/flox (Ehd1fl/fl mice in a 
predominantly C57BL/6 background (33, 36) were crossed with tamoxifen-
inducible CreERT2 expressing mice from Jackson Laboratories 
(Gt(ROSA)26Sortm1(cre/ERT2)Tyj; strain 008463) to generate Ehd1fl/fl; CreERT2 mice. 
Genotypes were confirmed by subjecting tail clip DNA to qRT-PCR analysis 
using the KAPA Mouse Genotyping kit (KAPA Biosystems) and primer pairs 
described in Table 2.2. Mice were treated humanely according to the National 
Institutes of Health (NIH) and The University of Nebraska Medical Center 
guidelines. Animal studies were pre-approved by the Institutional Animal Care 
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and Use Committee (#07-061-FC12). 
Bone Marrow-Derived Macrophages (BMDMs) 
Bone marrow was harvested from 8-12 week old mice by removing the 
femur bones, cutting the ends, and flushing with ice-cold PBS. Red blood cells 
were lysed with solute-free H2O, and the bone marrow was plated on tissue 
culture coated dishes for 16 hours to allow mature/non-progenitor cells to attach. 
The non-adherent progenitor population was collected by pipetting and re-plated 
in 15-cm Petri dishes (non-tissue culture treated). Cells were then incubated for 6 
days in BMDM media (RPMI w/ 15% FBS, 10% L929 supernatant and 1% 
penicillin/streptomycin) at 37oC and 5% CO2 to produce differentiated bone 
marrow-derived macrophages (BMDMs). Culture media was changed every 2 
days and cells were cultured for longer than 30 days. To assess the impact of 
EHD1 deletion, Ehd1fl/fl; CreERT2 BMDMs were either cultured in regular medium 
(wildtype EHD1 expression) or medium containing 200 nM 4-hydroxytamoxifen 
(TAM) for 4 days to induce EHD1 deletion. This protocol was based on the initial 
time course and titration studies to determine optimal culture conditions. An 
illustration of BMBM preparation is displayed in Figure 2.2 and for inducible gene 
deletion in Figure 2.3. 
Fluorescence Activated Cell Sorting (FACS) 
BMDMs were washed with ice-cold PBS and blocked for 10 minutes for 
non-specific binding with CD16/32 (Fc Blocker) and then incubated with 
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appropriate antibodies at a dilution of 1:400 and put in the dark and on ice for 
30min. Cells were then pelleted, washed with PBS twice, and suspended in 400 
µl of 0.1% BSA/PBS, put on ice, and protected from light. 
Quantitative Real-Time-PCR (qRT-PCR) 
RNA was isolated from BMDMs cultured on 10-cm tissue culture plates 
using the Trizol reagent, and 1 µg of total RNA was reverse transcribed using the 
QuantiTect Reverse Transcription Kit (QIAGEN). 10% volume of the reaction of 
the ensuing cDNA was used with QuantiTect SYBR Green qRT-PCR Kit 
(QIAGEN) for qRT-PCR of mouse CSF-1R, using the primer sequences in Table 
2.3. GAPDH was used as a control, and changes in CSF-1R were calculated 
using the threshold cycle method (55). Each reaction was performed in triplicate 
in a volume of 50 µL with primers at a final concentration of 250 nM. 
Immunoblotting (IB) 
Immunoblotting/Western blotting was performed as described (36). Briefly, 
BMDMs were washed with ice-cold PBS and lysed in ice-cold Triton X-100 lysis 
buffer (0.5% Triton X-100, 50 mM Tris pH 7.5, 150 mM sodium chloride, and 
EDTA-free protease inhibitor cocktail). The lysates were vortexed, centrifuged at 
13,000 rpm for 30 minutes at 4o C, and supernatants collected. Protein 
quantification was done by using a Thermo Scientific-Pierce Bicinchoninic acid 
(BCA) assay (cat. # 23225). 40 μg of lysate protein per sample was resolved by 
SDS/PAGE and transferred to a PVDF membrane (Millipore, cat. # IPVH00010). 
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The membranes were blocked in TBS/1% Bovine Serum Albumin (BSA), 
incubated with the appropriate primary antibodies diluted in TBS-0.1% Tween 20 
(BIO-RAD, cat. # 161-0781) overnight at 4°C. Next, membranes were washed in 
TBS-0.1% Tween (3 times for 10 minutes) followed by a 1-hour incubation with 
HRP-conjugated secondary antibody at room temperature. The membrane was 
washed in TBS-0.1% Tween (3 times for 10 minutes) each and ECL-based 
detection performed. 
Immunofluorescence (IF) 
Imaging using immunofluorescence was performed as previously 
described (56) with minor modifications. BMDMs were cultured on glass 
coverslips and fixed with 2% PFA/PBS for 5 min to assess the cell surface CSF-
1R signals (57). Cells were fixed and permeabilized in methanol for 10 minutes at 
-20oC to evaluate total CSF-1R. The cells were then blocked with 1% BSA/PBS 
for 30 minutes and incubated with primary antibodies in 1% BSA/PBS overnight. 
Cells were then washed with PBS (three times), BMDMs incubated with the 
appropriate fluorochrome-conjugated secondary antibody for 45 minutes at room 
temperature (RT), washed and mounted using Fluoromount-G (Southern 
Biotech, Cat. # 0100-01) or VECTASHEILD mounting medium (Vector 
Laboratories, Cat. # H-1400 and H-1500). Images were acquired using a 
LeicaCTR4000 inverted microscope equipped with a QICAM 12-bit color camera, 
12V 100 W halogen lamp, QCapture software and 60x oil lens (For CSF-1R) and 
a Zeiss 710 Meta Confocal Laser Scanning microscope (Carl Zeiss) using a 63× 
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objective with a numerical aperture of 1.0 and appropriate filters. Merged 
fluorescence pictures were generated and analyzed using ZEN® 2012 software 
from Carl Zeiss. 
3H-thymidine incorporation assay of cellular proliferation 
BMDMs were deprived of CSF-1 for 16 hours and plated in 48-well plates 
at 10,000 cells/well and allowed to attach overnight at 37ºC, 5% CO2. Cells were 
then treated with 30 ng/mL CSF-1 and allowed to proliferate for 2, 4 or 6 days. 
Cells were pulsed with 4 µCi/well of 3H-Thymidine for the last 6 hours of the 
assay. Radioactivity incorporated into DNA was collected by washing the cells 
with 10% TCA per well followed by 300 µl per well 0.2 N NaOH at room 
temperature to dissolve DNA. Each sample was transferred into vials with 5 mL 
of scintillation fluid and counts per minute (c.p.m.) were recorded with a 
scintillation counter. The protocol for 3H-thymidine incorporation assay of cellular 
proliferation is summarized in Figure 2.4.  
CFSE dye dilution assays to access macrophage proliferation 
Macrophages were cultured with recombinant CSF-1 (30 ng/mL) for 2, 4, 
or 6 days post initial CFSE population staining (Day 0) according to the 
manufacturer’s protocol. Dilution of CFSE fluorescence as an indicator of cell 
division was assessed via flow cytometry, and the geometric means of the 
histograms were used to evaluate the degree of cell division in response to CSF-
1. The protocol for CFSE dye dilution assay to access macrophage proliferation 
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is summarized in Figure 2.5. 
Macrophage CSF1-induced spreading assay 
BMDMs without (Control) or with (EHD1-KO) TAM were plated on 
coverslips and allowed to attach for 2 days. The BMDMs were then deprived of 
CSF-1 for 16 hours and then stimulated with 100 ng/mL CSF-1 for 10 minutes. 
Cells were fixed for 10 minutes with 4% PFA, washed with PBS (3 times for 10 
minutes), and stained using phalloidin-488 (ThermoFisher Scientific, cat. # 
A12381). ImageJ software was used to quantify the surface area of 
macrophages.  
Macrophage CSF1-induced migration assay 
BMDMs were deprived of CSF-1 for 4 hours and placed in the upper 
chambers of 5 µm pore inserts (Corning, cat. # 3421) at 1x105 cells per chamber 
in 100 µl RPMI without CSF-1. Cells were then allowed to migrate towards CSF-1 
(30 ng/mL) for 3 hours at 37°C. Cells on the bottom surface of membranes were 
fixed with 100% methanol and stained with HEMA for 5 minutes. Cells were 
visualized under a bright field microscope at 20x. Migrated cells were counted in 
10 fields per insert, and the total number of migrated cells was calculated for 
control and EHD1-KO BMDMs. 
[35S]-methionine/cysteine metabolic labeling of CSF-1R 
BMDMs were seeded at 5x106 cells/10-cm plate in CSF1-containing 
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medium and cultured for 16 hours. The cells were washed and incubated in 
methionine/cysteine-free RMPI-1640 medium supplemented with 15% FBS and 
30 ng/mL recombinant CSF-1 for 30 minutes at 37oC and pulsed with 0.1 mCi of 
[35S] for 15 minutes at 37oC. Cells were then washed and incubated with regular 
culture medium containing a 20-fold excess of unlabeled methionine/cysteine for 
0, 15, 30, and 60 minutes of chase.  
Immunoprecipitation (IP) 
Cells were rinsed with ice-cold PBS and immediately lysed in ice-cold 
Triton X-100 lysis buffer with EDTA-free protease inhibitor cocktail. Anti-CSF-1R 
immunoprecipitations were carried out using 500 μg samples of cleared lysate 
protein and anti-CSF-1R (C-20) antibody followed by exposure to Protein-A 
Sepharose beads. Samples were resolved by SDS/PAGE (8%). Gels were fixed, 
dried, and incubated with Auto-Fluor (National Diagnostics, cat. # LS-315) to 
amplify [35S] signals. Radiography was performed after films were exposed to the 
dried gels at -80oC in metal cassettes with intensifying screens. 
Statistics 
P-values were calculated by using an unpaired Student’s t-test and the 
threshold of significance is p<0.05. Data are shown graphically as means ± SEM 













Table 2.1. Genotypes of mice used in this study. 
 
Strain Designation Genotype 
Ehd1-WT Ehd1+/+ 
Ehd1-null Ehd1-/- 
Control Ehd1fl/fl; CreERT2 




Table 2.2. Genotyping PCR primer sequences. 
 





















Table 2.3. Real-time PCR primer sequences. 
 
Target Forward 5’ - 3’ Reverse 5’ - 3’ 
CSF-1R GCAGTACCACCATCCACTTGTA GTGAGACACTGTCCTTCAGTG
C 
EHD1 AGGACAGCCGCAAAGTCATA ACTGGACAGCATCAGCATCA 
EHD2 CTTGTTTTCCTTCCCGAACA  CAACGACCTAGTGAAACGGG 
EHD3 TCATGCCTGGAAAATCCTGT GATTTCGACAACAAGCCCAT 
EHD4 CGGCAAACCACTGTAAGACC GCATCAGCATCATCGACAGT 































Figure 2.1. Genotyping analysis. Genotyping analysis of Ehd1-WT and Ehd1-
null mice in comparison to the Jackson Laboratory C57BL/6J reference strain 
was carried out by DartMouse, Lebanon, NH using 1449 SNP Illumina Bead 
Chip. Each SNP output is color coded. Red represents C57Bl/6, blue represents 
heterozygous (B6 x 129), and yellow represents 129Sv. All analyzed mice (Ehd1-










Figure 2.2. BMDMs from Freshly Isolated bone marrow. Bone marrow was 
harvested from 8-12 week old mice by removing the femur bones, cutting the 
ends, and flushing with ice-cold PBS. Cells were then incubated for 6 days in 
BMDM media [RPMI w/ 15% FBS, 10% L929 supernatant (58) 1% 
penicillin/streptomycin] to produce bone marrow-derived macrophages (BMDMs). 
If inducible deletion was needed when using Ehd1fl/fl; CreERT2 BMDMs, cells were 
cultured in regular medium (wildtype EHD1 expression) or medium containing 












Figure 2.3. BMDMs with inducible EHD1 deletion. Ehd1fl/fl mice on a 
predominantly C57BL/6 background (33, 36) were crossed with tamoxifen-
inducible CreERT2 expressing mice from Jackson Laboratories 
(Gt(ROSA)26Sortm1(cre/ERT2)Tyj; strain 008463) to generate Ehd1fl/fl; CreERT2 mice. 
Bone marrow was harvested from 8-12 week old mice by removing the femur 
bones, cutting the ends, and flushing with ice-cold PBS. Cells were then 
incubated for 6 days in BMDM media [RPMI w/ 15% FBS, 10% L929 supernatant 
(58) 1% penicillin/streptomycin] to produce bone marrow-derived macrophages 
(BMDMs). If inducible deletion was needed when using Ehd1fl/fl; CreERT2 BMDMs, 
cells are further cultured in regular medium (wildtype EHD1 expression) or 
medium containing 200 nM 4-hydroxytamoxifen (TAM) for an additional 4 days to 
induce EHD1 deletion (EHD1-KO).   
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Figure 2.4. 3H-thymidine incorporation assays for cell proliferation. BMDMs 
were deprived of CSF-1 for 16 hours and plated in 48-well tissue culture plates at 
10,000 cells per well and allowed to attach overnight at 37 ºC, 5% CO2. Cells 
were then treated with 30 ng/mL CSF-1 and allowed to proliferate for 2, 4 or 6 
days. Cells were pulsed with 4 µCi/well of 3H-thymidine for the last 6 hours of the 
assay. Radioactivity incorporated into DNA was collected by washing the cells 
with 10% TCA per well followed by 300 µl per well 0.2 N NaOH at room 
temperature to dissolve DNA. Each sample was transferred into vials with 5 mL 
of scintillation fluid and counts per minute (c.p.m.) were recorded with a 
scintillation counter. Macrophages were cultured with recombinant CSF-1 (30 
ng/mL) for 2, 4 or 6 days post initial CFSE population staining (Day 0) according 
to manufacturer’s protocol. Dilution of CFSE fluorescence as an indicator of cell 
division was assessed via flow cytometry, and the geometric means of the 











Figure 2.5. CFSE dye dilution assays to assess macrophage proliferation. 
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Figure 2.5 CFSE dye dilution assays to access macrophage proliferation. 
After initial homogeneous labeling of the cell population at day 0 with the CFSE 
dye, cells were stimulated (30ng/mL CSF-1) to proliferate. Upon cell division, 
decreasing fluorescence (theoretically half) of the parent cell’s fluorescence is 
retained by each daughter population. Equal dye distribution dilution upon cell 
subsequent cellular divisions created different subpopulations, and when 
analyzed by flow cytometry the relative percentages of the original population in 
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Expression of EHD proteins in Ehd1-WT and Ehd1-null BMDMs 
To assess the potential role of EHD proteins in the context of CSF-1R, I 
chose to use primary BMDMs as these cells recapitulate in vitro the requirement 
of CSF1R-mediated signals for appropriate development and function (59). Flow 
cytometry analysis of mature macrophage marker F4/80 (58) confirmed the 
expected homogeneous differentiation of bone marrow progenitors into BMDMs 
when cultured in CSF1-containing medium (Figure 3.1).  
To assess EHD levels in BMDMs and to assure Ehd1-deletion, qRT-PCR 
and immunoblotting were performed for EHD family members. qRT-PCR 
revealed that Ehd1-WT BMDMs express EHD1 and EHD4 mRNA but not 
significant levels of EHD2 or EHD3 (Figure 3.2). Ehd1-null BMDMs had the same 
profile as Ehd1-WT BMDMs with the exception that Ehd1-null BMDMs had 
undetectable EHD1 mRNA expression (Figure 3.2). Western blot analysis of 
EHD1 and EHD4 expression confirmed the qRT-PCR results (Figure 3.2). 
Neither qRT-PCR nor Western blot analyses revealed a significant compensatory 
increase in the expression of EHD family members when EHD1 was deleted 
(Figure 3.2). These initial analyses provided a basis to explore a potential role of 
EHD1 in regulating CSF-1R signaling and traffic.  
Deletion of EHD1 in BMDMs leads to reduced CSF1-induced 
responses 
To assess implications of inducible EHD1 deletion on CSF1-induced 
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cellular responses, I first compared the CSF1-induced proliferation of BMDMs 
using two separate methods: 3H-thymidine incorporation and CFSE dye dilution 
assays. Both of these assays have previously been used to assess macrophage 
proliferation in response to CSF-1 [54, 55]. Both 3H-thymidine incorporation and 
CFSE dye dilution proliferation assays showed a significant deficit in CSF1-
induced macrophage proliferation in the Ehd1-null population of BMDMs (Figures 
3.3-3.5). 
As stimulation through CSF-1R is known to correlate with rapid 
macrophage spreading (62), I next conducted a spreading assay to examine the 
impact of EHD1 deletion on macrophage cellular spreading. Ehd1-WT and Ehd1-
null BMDMs were deprived of CSF-1 for 16 hours and then stimulated with CSF-
1 for 10 minutes. The cells were then fixed and stained (Phalloidin-488) to 
assess the extent of cell spreading by quantifying the surface area of individual 
macrophages in both Ehd1-WT and Ehd1-null BMDMs. Ehd1-null BMDMs 
exhibited reduced spreading in response to CSF-1 stimulation (Figure 3.6). 
Collectively, these results indicate that Ehd1-deletion in BMDMs impairs the 
CSF1-induced macrophage phenotype.  
Deletion of EHD1 in BMDMs leads to reduced CSF-1R signaling 
I next sought to determine the effect of EHD1 deficiency on CSF-1R 
signaling activation of the ERK pathway since macrophage proliferation is known 
to be mediated by this pathway (17). The levels of pERK upon CSF-1 stimulation 
were significantly lower in Ehd1-null as compared to Ehd1-WT BMDMs (Figure 
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3.7). Thus, Ehd1-deletion results in decreased CSF1-induced CSF-1R signaling 
in macrophages. 
Reduced surface CSF-1R expression in EHD1-KO BMDMs 
CSF-1R display at the cell surface is essential for CSF-1R 
activation/signaling by CSF-1 (17). Given the results above and the known role of 
EHD1 in the endocytic trafficking of cellular surface receptors (41–47), I next 
sought to determine if absence of EHD1 alters cell surface CSF-1R expression in 
BMDMs.  
Since BMDMs require CSF-1 for in vitro culture, surface levels of CSF-1R 
are low under steady state conditions due to continuous activation and lysosomal 
degradation of ligand-activated CSF-1R (25, 29). Therefore, I assessed the cell 
surface CSF-1R levels at 16 hours following the removal of CSF-1 from the 
culture medium (CSF-1 deprivation) in order to allow the newly synthesized CSF-
1R to accumulate at the cell surface. As expected, Ehd1-WT surface CSF-1R 
levels increased to a high level. In contrast, accumulation of cell surface CSF-1R 
on Ehd1-null BMDMs was significantly less after 16 hours CSF-1 deprivation 
(Figure 3.8). Thus, EHD1 deletion in BMDMs results in decreased surface CSF-
1R expression. 
EHD1 inducible deletion in BMDMs   
Our initial analysis thus far of BMDMs derived from whole-body Ehd1-null 
mice showed that EHD1 and EHD4 are expressed in BMDMs and that loss of 
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EHD1 led to reduced CSF-1R signaling, CSF-1R surface levels, cell proliferation, 
and cellular spreading (Figures 3.1-3.8). Thus, EHD1 functions as a positive 
regulator of CSF-1R signaling in macrophages. 
While our existing Ehd1-null mice provide a reasonable approach, I sought 
to eliminate any macrophage developmental bias in the whole body Ehd1-null 
mice. Moreover, I used BMDMs isolated from Ehd1fllfl; CreERT2 mice without 
(Control) and with (EHD1-KO) tamoxifen (TAM) treatment to confirm my findings 
that Ehd1 is a positive regulator of CSF-1R signaling in macrophages.  
Inducible deletion of EHD1 in BMBMs from Ehd1
fl/ fl; CreERT2 mice. 
To determine if deletion of inducible EHD1 deletion had a functional 
impact in BMDMs, I first assessed whether or not EHD1-KO bone marrow 
progenitors could be differentiated into BMDMs and subsequently have EHD1 
deletion induced by TAM treatment in vitro.  Ehd1fl/fl; CreERT2 BMDMs cultured 
in the absence or presence of TAM were stained with F4/80 antibody and 
analyzed via Facilitated Analysis Cell Sorting (FACS). Greater than 99% of 
BMDMs without (Control) and with (EHD1-KO) TAM treatment stained positive 
for F4/80+ (Figure 3.9). Thus, these results demonstrate the ability of bone 
marrow from Ehd1fl/fl; CreERT2 mice to differentiate into mature macrophages.  
Next, to confirm EHD family expression in BMDMs from Ehd1
fl/ fl; CreERT2 
mice without (Control) and with (EHD1-KO), qRT-PCR was carried out. BMDMs 
from Ehd1
fl/ fl; CreERT2 mice without (Control) and with (EHD1-KO) expressed 
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EHD1 and EHD4 mRNA but did not express significant levels of EHD2 or EHD3 
(Figure 3.10A). Furthermore, BMDMs cultured in the presence (EHD1-KO) of 
TAM showed undetectable EHD1 mRNA expression (Figure 3.10A). Thus, these 
data confirmed an efficient and effective knockout of EHD1 (EHD1-KO) with TAM 
treatment. Western blot analysis of EHD1 and EHD4 expression confirmed the 
qRT-PCR results of a successful EHD1-KO (Figure 3.10B). Neither qRT-PCR nor 
Western blot analyses revealed a significant compensatory increase in the 
expression of other EHD family members when EHD1 is deleted (Figure 3.10). 
These findings solidified our initial findings of EHD family protein expression in 
BMDMs using whole-body Ehd1-null mice. 
Tamoxifen is not toxic to BMDMs in vitro  
I next performed control experiments to verify that any phenotypic effects I 
observed using EHD1-KO BMDMs were bona fide effects of EHD1 deletion and 
not effects of tamoxifen treatment. To exclude the possibility that reduced CSF-1 
elicited biological responses in tamoxifen-induced EHD1-KO BMDMs were not 
due to incidental toxicity of tamoxifen, as observed in previously reported 
systems (63), I cultured BMDMs from Ehd1fl/fl mice (lacking CreERT2), with or 
without TAM, and assessed their CSF1-induced proliferation using the CFSE dye 
dilution assay. Untreated vs. TAM-treated Ehd1fl/fl BMDMs exhibited comparable 
proliferative responses to CSF-1 (Figure 3.11), indicating TAM treatment did not 
alter in vitro BMDM CSF-1R signaling.  
To further control for possible toxic side-effects of TAM treatment, I 
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assessed apoptosis with Annexin V and propidium iodide (PI) staining using 
Ehd1fl/fl BMDMs cultured with or without TAM. The double staining with Annexin 
V and PI was analyzed by flow cytometry and did not reveal any significant 
differences in the percentage of apoptotic cells in Ehd1fl/fl BMDMs cultured with 
or without TAM (Figure 3.12). These assays showed a lack of TAM treatment 
toxicity or attenuation of CSF1-induced CSF-1R signaling responses in BMDMs. 
Inducible EHD1-KO results in reduced CSF1-induced 
macrophage functions 
To assess the role of EHD1 in macrophage CSF1-induced cellular 
responses, I assayed the effects of CSF1-induced proliferation on BMDMs 
derived from Ehd1fl/fl; CreERT2 mice without (Control) and with (EHD1-KO) TAM 
treatment. I used two independent methods to assess macrophage proliferation 
as with my initial studies using BMDMs from Ehd1-null mice: 3H-thymidine 
incorporation and CFSE dye dilution assays. Both assays showed EHD1-KO 
macrophages had significantly reduced proliferative responses when stimulated 
with CSF-1 (Figures 3.13-3.15). These findings confirmed my initial findings 
using BMDMS from Ehd1-WT and Ehd1-null mice. 
Next, I sought to examine the impact of EHD1 deletion on CSF1-induced 
macrophage functional response. BMDMs cultured without (Control) or with 
(EHD1-KO) TAM were subjected to a spreading assay. EHD1-KO BMDMs 
exhibited reduced spreading in response to CSF-1 stimulation (Figure 3.16). 




To further assess the impact of EHD1 deletion on CSF1-induced 
macrophage functional responses, I conducted a trans-well migration. This 
migration assay is a well-established way to assess macrophages response to 
CSF-1 stimulation (64). Compared to the control group, EHD1-KO BMDMs 
showed a significant reduction in migration (Figure 3.17).  
Collectively, these results demonstrated that EHD1-KO in BMDMs leads 
to a significant deficit in CSF1-induced cellular responses. Furthermore, EHD1 
appears to mediate CSF1-induced macrophage function via regulation of CSF-
1R signaling. These findings solidified my initial findings using Ehd1-WT and 
Ehd1-null BMDMS. 
EHD1-KO BMDMs have reduced CSF-1R signaling 
Next, I assessed the effects of EHD1-KO on CSF-1R signaling 
downstream activation of the MAPK pathway, which is known to modulate 
cellular proliferation (65, 66). After 16 hours of CSF-1 deprivation, the total CSF-
1R levels were lower in the EHD1-KO compared to Control BMDMs (Figure 3.18; 
0-time points). Commensurate with diminished CSF-1R, accumulation of pERK in 
EHD1-KO BMDMs was significantly lower than in control BMDMs (Figure 3.18). 
These findings suggest diminished CSF-1R signaling is a consequence of EHD1 
absence in macrophages and is likely due to decreased total CSF-1R protein. 
These findings solidify our findings using Ehd1-WT and Ehd1-null BMDMS. 
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CSF-1R internalization and degradation are similar in EHD1-KO 
BMDMs 
Since EHD1 has thus far been primarily characterized as a regulator of the 
recycling back to the cell surface of previously internalized cell surface receptors 
(30), I wished to determine if the post-endocytic traffic of CSF-1R may also be 
regulated by EHD1. CSF-1 stimulation of BMDMs is known to induce rapid CSF-
1R internalization (~5 minutes), transport to macropinosomes (~5–15 minutes) 
and lysosomal degradation (~30 minutes) (23, 25, 57). Both Control and EHD1-
KO macrophages were deprived of CSF-1 for 16 hours followed by stimulation 
with CSF-1 and both surface and total CSF-1R expression was assessed by 
immunofluorescence microscopy. No apparent difference in the kinetics of CSF-
1R internalization (Figures 3.19) or degradation (Figure 3.20) was observed 
between Control and EHD1-KO BMDMs. However, consistent with experiments 
using Ehd1-WT and Ehd1-null BMDMs, a markedly lower surface and total CSF-
1R levels were seen in EHD1-KO BMDMs prior to CSF-1 addition (16 hours after 
CSF-1 deprivation).  
Reduced surface CSF-1R expression in EHD1-KO BMDMs 
To further understand the decreased surface CSF-1R expression 
observed in EHD1-KO BMDMs (Figure 3.19), I assessed the cell surface CSF-1R 
levels using flow cytometry after 2, 4, 8 or 16 hours of CSF-1 deprivation. Initially, 
low CSF-1R surface levels increased steadily over time in Control BMDMs; 
however, surface CSF-1R in EHD1-KO BMDMs accumulated at a significantly 
61 
 
lower rate. Surface expression of CSF-1R was considerably less at all-time 
points following CSF-1 deprivation in EHD1-KO as compared to Control BMDMs 
(Figures 3.21 and 3.22). Thus, loss of EHD1 leads to reduced CSF-1R present at 
the cell surface in BMDMs available for activation by CSF-1. These findings 
agree with my initial findings using Ehd1-WT and Ehd1-null BMDMS. 
EHD1 deletion results in depletion of CSF-1R protein in BMDMs 
To investigate the mechanism responsible for reduced cell surface 
expression of CSF-1R on EHD1-KO BMDMs, I first examined (by western 
blotting) the accumulation of total cellular CSF-1R protein after CSF-1 was 
removed from the culture medium. Ehd1fl/fl; CreERT2 BMDMs grown in regular 
CSF1-containing medium without (Control) or with (EHD1-KO) TAM treatment 
were deprived of CSF-1 for 2, 4, 8 or 16 hours. At the given time-points, cells 
were lysed and subsequently analyzed by immunoblotting for total CSF-1R 
levels. Notably, EHD1-KO BMDMs showed a significant and substantial 
reduction in the total CSF-1R protein levels at each CSF-1 deprivation time point 
(Figures 3.23 and 3.24). Thus, EHD1-KO BMDMs are characterized by reduced 
total CSF-1R. 
EHD1 functions to transport newly synthesized CSF-1R to the 
cell surface 
Given the reduction in surface and total CSF1R in EHD1-KO BMDMs, I 
carried out qRT-PCR analysis to assess the levels of CSF-1R mRNA expression 
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(synthesis) in Control and EHD1-KO BMDMs. Ehd1
fl/fl; CreERT2 BMDMs cultured 
without (Control) or with (EHD1-KO) TAM were harvested under steady state 
culture conditions (with CSF-1) or 16 hours after CSF-1 removal from the culture 
medium. The CSF-1R mRNA levels increased nearly 50% when control BMDMs 
cultured under steady-state conditions (with CSF-1) were changed to CSF1-free 
medium for 16 hours. CSF-1R mRNA levels were not significantly different in 
EHD1-KO compared to those of Control BMDMs (Figure 3.25). Thus, I concluded 
the reduction in total CSF-1R levels in EHD1-KO BMDMs was not likely due to a 
defect in CSF-1R synthesis. 
To more rigorously assess if EHD1 deletion affects CSF-1R protein 
synthesis and/or its post-translational maturation and transport to the cell 
surface, I performed metabolic pulse labeling with [35S]-methionine/cysteine. 
Under these conditions, newly synthesized and mature CSF-1R that reaches the 
cell surface will bind CSF-1, undergo immediate activation, be targeted for 
degradation in the lysosome, and result in a reduction in radioactive signals of 
mature CSF-1R at later time points of the chase experiment. Equal amounts of 
lysates collected at various time points were subjected to anti-CSF-1R 
immunoprecipitation to visualize the immature and mature CSF-1R polypeptides. 
The signals of immature CSF-1R synthesized during pulse-labeling (time 0) were 
comparable between control and EHD1-KO BMDMs (Figure 3.26; lower band), 
thus excluding any alteration in the rate of protein synthesis as a determinant of 
the observed reduced total CSF-1R levels in EHD1-KO cells previously seen in 
Figure 3.23.  
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Analysis at various times during chase showed that the conversion of 
immature CSF-1R to a higher molecular weight, a fully glycosylated form known 
to be generated in the Golgi (17) was similar to a majority of immature forms 
converting to mature forms by 30 min of chase (Figure 3.26). Notably, mature 
CSF-1R signals in control BMDMs were sharply lower by 60 min of chase, 
reflecting its arrival at the cell surface and subsequent CSF1-induced 
internalization and degradation (Figure 3.26) (26). In contrast, the mature CSF-
1R signals remained high, and nearly unaltered, at 60 min of the chase in EHD1-
KO BMDMs (Figure 3.26), indicative of a block in the surface transport of newly 
synthesized and mature CSF-1R. These observations support the conclusion 
that EHD1 is required at a post-Golgi glycosylation step in the surface transport 
of the newly synthesized and fully glycosylated CSF-1R. 
CSF-1R was found localized to this EHD1+/GM130+ compartment 
Given the results of pulse-chase analyses, I sought to determine if EHD1 
co-localizes with CSF-1R at the Golgi apparatus. Three-color confocal imaging 
was performed on fixed and permeabilized BMDMs previously cultured without 
(Control) or with (EHD1-KO) TAM for 2, 4, 8, and 16 hours after removal of CSF-
1 to allow CSF-1R synthesis and accumulation. In control BMDMs, a pool of 
EHD1 co-localizes with the Golgi marker GM130, and a pool of CSF-1R was 
found localize to this EHD1+/GM130+ compartment (Figure 3.27). As expected, 
no EHD1 staining was detected in BMDMs rendered EHD1-KO by culture in the 
presence of TAM (Figure 3.27). The EHD1-KO BMDMs also exhibited a pool of 
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CSF-1R localized to GM130+ Golgi compartment, with lower CSF-1R signals 
near the cell surface (Figure 3.27).   
These results, together with those of the metabolic pulse-chase, support 
the conclusion that EHD1 is involved in directing the Golgi-localized (newly 
synthesized) CSF-1R to the cell surface. 
Newly synthesized CSF-1R transits to lysosomes for 
degradation in EHD1-KO BMDMs 
In view of a block in the post-Golgi transport of CSF-1R to the cell surface 
in EHD1-KO BMDMs, combined with reduced total CSF-1R levels without any 
alterations in its initial synthesis and glycosylation, I hypothesized that EHD1 was 
required for the efficient sorting of Golgi-localized CSF-1R towards the cell 
surface, and that absence of this mechanism resulted in CSF-1R transit to the 
lysosome for degradation. BMDMs cultured in the absence (Control), or presence 
(EHD1-KO) of TAM were switched from regular to CSF1-free medium for 4 hours 
either in the absence or presence of lysosomal proton pump blocker Bafilomycin 
A1 (Baf-A1). Western blot analysis demonstrated the expected lower levels of 
total CSF-1R observed previously in EHD1-KO vs. control BMDMs cultured in the 
absence of Baf-A1 (Figure 3.28; first and third lanes).  
The inclusion of Baf-A1 led to a dramatic and statistically significant 
increase in CSF-1R levels in EHD1-KO BMDMs compared to the no Baf-A1 
control, and nearly approaching the levels in Control BMDMs (Figure 3.28). 
These results suggest that CSF-1R rapidly transits from the Golgi to the 
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lysosome in EHD1-KO BMDMs and undergoes degradation. 
To further demonstrate this proposed mechanism, I carried out confocal 
imaging of Control and EHD1-KO BMDMs cultured for 4 hours in Baf-A1. 
BMDMs from both groups were stained for CSF-1R and LAMP1 (a lysosomal 
marker). In contrast to a small pool of CSF-1R that localized in LAMP1+ 
lysosomes in control BMDMs, a significantly higher level of co-localization 
between CSF-1R and LAMP1 was seen in EHD1-KO BMDMs (Figure 3.29).  
Overall, these results support the conclusion that EHD1 helps in the 
transport of CSF-1R from a Golgi sorting compartment to the cell surface. 
Furthermore, CSF-1R is shunted to the lysosome in EHD1-KO BMDM, resulting 

























Figure 3.1. BMDMs defined by F4/80+ flow cytometry staining. BMDMs were 
stained on day 6 of bone marrow culture from Ehd1-WT and Ehd1-null mice for 












Figure 3.2. EHD family expression in Ehd1-WT and Ehd1-null BMDMs. (A) 
Quantitative real-time-PCR analysis of EHD family proteins in BMDMs. Data was 
normalized to GAPDH and was expressed as a fold change with EHD1 
expression in Ehd1-WT BMDMs set to 1. (B) Lysate from Ehd1-WT and Ehd1-
null BMDMs. Immunoblotting was for EHD1, EHD4, and HSC70. Note specific 
deletion of EHD1 protein in BMDMs matured from Ehd1-null mice, but not from 
Ehd1-WT mice. Representative data from 3 separate biological replicates are 
shown (mean ± SEM; * = p < 0.05, n.s. = not significant).  
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Figure 3.3. 3H-thymidine proliferation assay using BMDMs. BMDM 
proliferation as measured by 3H-thymidine incorporation. Ehd1-WT and Ehd1-null 
BMDMs were stimulated with CSF-1 at 0, 15, 30 or 60 ng/mL for 3 days. 
Representative data from 3 separate biological replicates are shown (mean ± 












Figure 3.4. CFSE assays using Ehd1-WT and Ehd1-null BMDMs. (A) BMDM 
proliferation as measured by CFSE dye dilution assay. Ehd1-WT and Ehd1-null 
BMDMs were stained with CFSE dye (day 0) and subsequently stimulated with 
30 ng/mL recombinant CSF-1 for 3, 5, or 7 days. (B) Quantification of Mean 
Fluorescence Intensity (MFI) CFSE dye dilution assay from Figure 3.4B. MFI fold 
change was normalized relative to Control BMDMs. Representative data from 3 











Figure 3.5. CFSE population differences in Ehd1-WT and Ehd1-null BMDMs. 
BMDM proliferation as measured by CFSE dye dilution assay. Ehd1-WT and 
Ehd1-null BMDMs were stained with CFSE dye (day 0) and subsequently 
stimulated with 30 ng/mL recombinant CSF-1 for 3 days. Then population 
modeling of cell population divisions was carried out using software available 
through the Flow Cytometry Core Facility. The percentages in the red boxes 
indicate the percentage of the population in the highest generation. 












Figure 3.6. Ehd1-null BMDMs have reduced CSF1-induced cellular 
spreading. Cells were starved of CSF-1 overnight and then stimulated with 100 
ng/mL CSF-1 for 10 minutes. Fixation and staining was performed with phalloidin 














Figure 3.7. CSF-1 stimulation induces CSF-1R signaling. Reduced CSF1-
induced pERK levels in Ehd1null BMDMs. Ehd1-WT and Ehd1-null BMDMs were 
CSF1-deprived for 16 hours and subsequently stimulated for 10 minutes with 100 
ng/mL CSF-1 for 3, 10, 30,90, and 270 minutes. 40 µg aliquots of sample protein 
lysate were immunoblotted with the indicated antibodies. Representative data 




Figure 3.8. Ehd1-null BMDMs have decreased surface CSF-1R expression 








Figure 3.8. Ehd1-null BMDMs have decreased surface CSF-1R expression 
upon CSF-1 deprivation. (A) Flow cytometry analysis for CSF-1R surface 
expression. Ehd1-WT and Ehd1-null BMDMs were deprived of CSF-1 for 16 
hours and subsequently stained with anti-CSF-1R antibody and analyzed by flow 
cytometry. Grey histograms are IgG control. (B) Quantification of CSF-1R surface 
expression from Figure 3.8A. Data are presented as the fold change of MFIs, 
with control BMDMs deprived of CSF-1 for 16 hours set to 1 (mean ± SE; n = 3; 
*p<0.05). Representative data from 3 separate biological replicates are shown 










Figure 3.9. F4/80+ Control and EHD1-KO BMDMs. BMDMs were stained on 
day 10 of bone marrow culture from Ehd1
fl/fl
CreERT2 mice for mature macrophage 
















Figure 3.10. EHD family expression in control and inducible EHD1-KO 
BMDMs. Quantitative real-time-PCR analysis of EHD family proteins in BMDMs. 
Data was normalized to GAPDH and was expressed as a fold change with EHD1 
expression in Ehd1
fl/fl





CreERT2 BMDMs cultured for 4 days -/+TAM. Note specific 
deletion of EHD1 protein in BMDMs matured from Ehd1
fl/fl
CreERT2 mice, but not 
from Ehd1
fl/fl
 mice. Representative data from 3 separate biological replicates are 














Figure 3.11. Lack of CSF-1 response alteration due to TAM treatment. (A) 
BMDMs from Ehd1
fl/f 
mice -/+TAM were labeled with CFSE and allowed to 
proliferate for 4 days in the presence of 30 ng/mL CSF-1 (B) Quantification of 
CFSE dye dilution assay from Figure 3.11A; CFSE MFI normalized to Ehd1
fl/fl
 
BMDMs +TAM. Representative data from 3 separate biological replicates are 












Figure 3.12. Lack of apoptosis toxicity of TAM in BMDMs. Ehd1
fl/fl
 BMDMs 
cultured with or without TAM were stained with anti-Annexin V and propidium 
iodide followed by flow cytometry analysis to assess the proportion of apoptotic 











Figure 3.13. EHD1 deletion results in reduced proliferation. (A) BMDM 
proliferation via 3H-thymidine incorporation. Ehd1
fl/fl; CreERT2 BMDMs cultured 
without (Control) or with (EHD1-KO) TAM were stimulated with CSF-1 at 0, 15, 
30 or 60 ng/mL for 2, 4 or 6 days. Representative data from 3 separate biological 
replicates are shown (mean ± SD; *p<0.05, n.s. = not significant).  
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Figure 3.14. EHD1-KO BMDMs have reduced CSF1-induced proliferation. 
(A) BMDMs proliferation with CFSE (dye dilution assay). Ehd1
fl/fl; CreERT2 
BMDMs were previously cultured without (Control) or with (EHD1-KO) TAM were 
stained with CFSE dye (day 0) and then stimulated with 30 ng/mL recombinant 
CSF-1 for 2, 4, or 6 days. (B) Quantification of Mean Fluorescence Intensity 
(MFI) CFSE from Figure 3.15B. MFI fold change was normalized relative to 
control BMDM population. Representative data from 3 separate biological 










Figure 3.15. CFSE population model in BMDMs. BMDMs proliferation was 
monitored with the CFSE dye dilution assay. Ehd1
fl/fl; CreERT2 Control or EHD1-
KO BMDMs were stained with CFSE dye (day 0) and then stimulated with 30 
ng/mL recombinant CSF-1 for 5 days. Software available at the UNMC Flow 
Cytometry facility was used to model the populations according to the number of 
divisions each BMBM populations had undergone. Representative data from 3 










Figure 3.16. EHD1 deletion results in reduced spreading. (A) Microscopy 
analysis of CSF1-induced macrophage cell spreading. Ehd1
fl/fl; CreERT2 BMDMs 
were cultured without (Control) or with (EHD1-KO) TAM, CSF-1 deprived for 16 
hours, and subsequently stimulated with 100 ng/mL CSF-1 for 10 minutes. Cells 
were then fixed, permeabilized, and stained for polymerized actin using 
conjugated phalloidin—488 followed by confocal microscopy. (B) Quantification 
of cellular spreading (Figure 3.16A) via calculating cell surface area 
(corresponding to phalloidin staining) using ImageJ software. 100 cells were 
counted for 3 independent experiments. Cell surface area was normalized to 
control BMDM population. Representative data from 3 separate biological 
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3.17. EHD1-KO BMDMs have reduced migration. (A) Transwell migration 
assay. Ehd1
fl/fl; CreERT2 BMDMs cultured without (Control) or with (EHD1-KO) 
TAM were deprived of CSF-1 for 4 hours and allowed to migrate towards CSF-1 
(30 ng/mL) in the lower chamber of Boyden Transwell chambers. Filters were 
HEMA stained and photographed at 20x. (B) Quantification of migration assays 
from Figure 3.17A. Total cells migrated were normalized to control BMDM 
population. Representative data from 3 separate biological replicates are shown 












3.18. EHD1-KO BMDMs have decreased pERK downstream CSF-1R 
signaling. (a) Reduced CSF1-induced pERK levels in EHD1-KO BMDMs. 
Ehd1
fl/fl; CreERT2 BMDMs were deprived of CSF-1 for 16 hours and then 
stimulated with 100ng/mL CSF-1 for 10 minutes. 40 µg aliquots of sample protein 
lysate were immunoblotted with the indicated antibodies. (b) The quantification of 
Figure 3.18A is shown. The relative levels of pERK signals were normalized to 
HSC70 and expressed as a fold change by setting the control BMDM population 
stimulated with CSF-1 for 10 minutes at 1. Representative data from 3 separate 










Figure 3.19. EHD1 deletion has no significant effect on activated CSF-1R 
internalization. (A) No impact of EHD1 deletion on ligand-induced 
downregulation of surface CSF-1R. Ehd1
fl/fl; CreERT2 BMDMs cultured without 
(Control) or with (EHD1-KO) TAM were deprived of CSF-1 for 16 hours and 
stimulated with 100 ng/mL CSF-1 for 0, 2.5, 5 or 10 minutes were fixed and 
stained for surface CSF-1R followed by immunofluorescence microscopy 
analysis. (B) Quantification of the data in Figure 3.19A is displayed. 
Representative data from 3 separate biological replicates are shown (mean ± 










Figure 3.20. EHD1 deletion has no significant effect on activated CSF-1R 
degradation. BMDMs were prepared as in 3.28A and stimulated with CSF-1 for 
0, 2.5, 5, 10 or 30 minutes. Cells were fixed, permeabilized, and stained for total 
CSF-1R and imaged using immunofluorescence microscopy. (B) Quantification 
of the data in Figure 3.20A is displayed. Representative data from 3 separate 











3.21 EHD1-KO BMDMs have reduced surface CSF-1R expression. (A) Live-
cell flow cytometry analysis. Ehd1fl/fl; CreERT2 BMDMs were cultured without 
(Control) or with (EHD1-KO) TAM were switched from CSF1-containing to CSF1-
free medium for 2, 4, 8, or 16 hours and live cells were stained with anti-CSF-1R 
antibody followed by flow cytometry analysis. Grey histograms are IgG control. 
(B) Quantification of CSF-1R surface expression from Figure 3.21A is shown. 
Data are presented as the fold change of MFIs, with control BMDMs deprived of 
CSF-1 for 16 hours set to 1. Representative data from 3 separate biological 













3.22 EHD1 deletion in BMDMs results in reduced surface CSF-1R 
expression. (A) Immunofluorescence analysis of surface CSF-1R. Ehd1fl/fl; 
CreERT2 BMDMs were cultured as in Figure 3.21 but on coverslips, fixed with 
2% PFA for 5 minutes and stained with anti-CSF-1R antibody followed by 
imaging to visualize surface CSF-1R accumulation over time. (B) Quantification 
of data from Figure 3.22A. Representative data from 3 separate biological 




Figure 3.23. EHD1 deletion in BMDMs leads to a reduction in total CSF-1R, 






3.23 EHD1 deletion in BMDMs leads to a decrease in total CSF-1, 
demonstrated using immunoblotting. (A) Ehd1
fl/fl; CreERT2 BMDMs cultured 
without (Control) or with (EHD1-KO) TAM were switched from CSF1-containing 
to CSF1-free medium for 2, 4, 8 or 16 hours, and 40 µg aliquots of lysate protein 
were analyzed by immunoblotting with anti-CSF-1R (upper), anti-EHD1 (to show 
EHD1 deletion) and anti-HSC70 (loading control). (B) Quantification of CSF-1R 
signals from data in Figure 3.23A. The CSF-1R band pixels were quantified from 
scanned blots using ImageJ software, normalized based on HSC70 and 
expressed as a fold change by setting total CSF-1R from control BMDMs 
deprived of CSF-1 for 16 hours to 1. Representative data from 3 separate 











Figure 3.24. EHD1-KO BMDMs have reduced total CSF-1R using IF. (A) 
Analysis of total CSF-1R using immunofluorescence microscopy. BMDMs 
cultured as in A but on coverslips were fixed, permeabilized, and stained for with 
anti-CSF-1R antibody to visualize total CSF-1R. (B) Quantification of data from 
Figure 3.24A. Representative data from 3 separate biological replicates are 










Figure 3.25. EHD1 deletion does not affect CSF-1R synthesis. EHD1 deletion 
does not affect CSF-1R mRNA expression. RNA was isolated from Ehd1fl/fl; 
CreERT2 BMDMs cultured without (Control) or with (EHD1-KO) TAM were grown 
under steady state conditions (with CSF-1) and without CSF-1 for 16 hours, 
harvested, and quantitative qRT-PCR was performed. Data were normalized to 
GAPDH and expressed as a fold change relative to CSF-1R mRNA expression of 
control BMDMs at steady state. Representative data from 3 separate biological 




Figure 3.26. EHD1-KO deletion reduces transport of newly synthesized 






Figure 3.26. EHD1-KO reduces transport of newly synthesized CSF-1R to 
the cell surface. Metabolic pulse-labelling to show unaltered translation and 
maturation with a block of surface transport of newly synthesized CSF-1R in 
EHD1-KO BMDMs. Ehd1fl/fl; CreERT2 BMDMs cultured without (Control) or with 
(EHD1-KO) TAM were metabolically pulse-labeled with [35S] for 15 min and 
subjected to chase in unlabeled methionine/cysteine-enriched medium in the 
presence of CSF-1 for the indicated times followed by cell lysis. 40 µg aliquots of 
sample lysates were subjected to anti-CSF-1R immunoprecipitation followed by 
autoradiography. Lower band: immature/non-glycosylated CSF-1R; upper band: 
mature/fully glycosylated CSF-1R. Note comparable lower band signals at time 0 
and similar rates of conversion to the upper band; however, the mature upper 
band signals are lost in control BMDMs but remain intact in EHD1-KO BMDMs. 











Figure 3.27 CSF-1R co-localizes to a EHD1+/GM130+ compartment. 
Confocal immunofluorescence. Co-localization of EHD1 with CSF-1R at the Golgi 
apparatus. Ehd1fl/fl; CreERT2 BMDMs cultured without (Control) or with (EHD1-KO) 
TAM were switched from CSF1-containing medium to CSF1-free medium for 2, 
4, 8 or 16 hours and subsequently fixed, permeabilized and stained for CSF-1R 
(green), EHD1 (Red) and GM130-Golgi marker (Blue) and analyzed by confocal 













Figure 3.28. EHD1-KO BMDMs have increased CSF-1R lysosomal 
degradation. (A) Western blot analysis to show recovery of total CSF-1R levels 
in EHD1-KO BMDMs upon inhibition of lysosomal degradation. Ehd1
fl/fl; CreERT2 
BMDMs cultured without (Control) or with (EHD1-KO) TAM were switched from 
CSF1-containing medium to CSF1-free medium for 4 hours in the absence (-Baf-
A1) or presence (+Baf-A1) of lysosomal inhibitor: Baf-A1, 100 nM. 40 µg aliquots 
of sample protein lysates were immunoblotted for total CSF-1R (Top), HSC70 
(central; loading control) and EHD1 (bottom; to show EHD1 deletion). (B) 
Quantification of total CSF-1R signals from Figure 3.29A. Data were normalized 
to HSC70 signals and expressed as a fold change relative to values for the 
control BMDM population without Baf-A1 treatment. Representative data from 3 










Figure 3.29. EHD1-KO BMDMs shunt CSF-1R to the lysosome. (A) 
Representative confocal immunofluorescence image showing co-localization of 
CSF-1R in LAMP1+ lysosomes of EHD1-KO BMDMs upon lysosome inhibition 
via Baf-A1. Ehd1
fl/fl; CreERT2 BMDMs cultured without (Control) or with (EHD1-
KO) TAM were switched from CSF1-containing to CSF1-free medium for 4 hours 
in the presence of 100 nM Baf-A1. Cells were fixed, permeabilized, and stained 
for analysis utilizing immunofluorescence: CSF-1R (red) and LAMP1 (green); 
merged pictures on right show co-localization (yellow). (B) Quantification of CSF-
1R and LAMP1 co-localization from Figure 3.29A. Co-localization of CSF-1R and 
LAMP1 fluorescence signals was assessed in 50 cells each in 3 independent 
experiments to determine the co-localization coefficient ± SEM (n = 150). 




















The material covered in the following chapter is the topic of the following published article: 
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CSF-1 receptor signalling is governed by pre-requisite EHD1 mediated receptor display on the 
macrophage cell surface. 
 





The CSF-1R is essential for the development and diverse functions of the 
monocyte-macrophage lineage, which includes specialized tissue-specific cells 
such as microglia in the central nervous system (CNS) (67). Abnormal CSF1R-
dependent macrophage functions resulting from aberrant CSF-1R dependent 
signaling contribute to a variety of human diseases (7, 15, 68, 69). A pre-
requisite for all CSF1R-mediated macrophage functions is the delivery and 
display of the receptor at the cell surface. This requirement of macrophage cell 
surface presentation of CSF-1R is due to the initial activation step of ligand 
(CSF-1) stabilization of the dimerized form of the receptor tyrosine kinase (17). 
Without this key initial step, CSF-1R signaling cannot occur and macrophage 
biology will be compromised. Mechanisms that govern the post-synthesis 
maturation and traffic of CSF-1R to the macrophage cell surface are therefore 
biologically pivotal. Furthermore, understanding these mechanisms will likely lead 
to the development of effective therapies and treatments of devastating human 
conditions aimed at targeting the inhibition of CSF-1R signaling. 
In this dissertation, I have used primary bone marrow-derived 
macrophages (BMDMs) from constitutive and inducible knockout mouse models 
to provide evidence that EHD1, a member of the EHD protein family of endocytic 
recycling regulators, serves a novel and critical role in ensuring Golgi-to-cell 
surface traffic of CSF-1R. I show that this novel gate-keeper function of EHD1 
helps direct the post-synthesis traffic itinerary of CSF-1R away from an alternate 
fate of delivery to lysosomes where it is degraded. My experiments demonstrate 
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that EHD1-dependent cell surface transport of CSF-1R ensures subsequent 
ligand-induced CSF-1R signaling and macrophage functional activation. EHD1, a 
member of the EHD family of endocytic recycling regulators, has only previously 
been shown to function in receptor recycling and retrograde traffic from the early 
endosome to the Golgi. I report in this dissertation a new critical function for 
EHD1 in the presentation of CSF-1R upon the macrophage cell surface. This 
novel gate-keeper function of EHD1 helps direct the post-synthesis traffic 
itinerary of CSF-1R away from an alternate fate of delivery to lysosomes where it 
is degraded. My data demonstrate that EHD1 functions in the cell surface 
transport of CSF-1R—ensuring subsequent ligand-induced cellular activation. 
Furthermore, a novel function for EHD1 as a positive regulator of basal post-
synthetic CSF-1R traffic to the cell surface has been revealed. Previously known 
only to function in recycling of internalized receptors back to the cell surface (41–
47) these findings define a new role for a member of the entire EHD protein 
family,. 
To investigate the role of EHD1 in the context of CSF-1R signaling in 
macrophages, I chose the physiologically relevant model (due to CSF-1R 
dependence in vitro) of primary bone-marrow derived macrophages (BMDMs) 
from constitutive Ehd1-null mice as well as a novel inducible EHD1 deletion 
mouse model only available in our laboratory. We engineered constitutive and 
inducible EHD1-deletion mouse models. The inducible deletion has been 
engineered such that the incorporation of a tamoxifen-inducible CreERT2 allele 
allows inducible deletion of Ehd1fl/fl under controlled conditions of TAM treatment.  
128 
 
Using the BMDMs from our laboratories’ constitutive EHD1 deletion 
mouse model, the initial analysis showed that BMDMs only express EHD1 and 
EHD4 and not significant levels of EHD2 or EHD3. Furthermore, BMDMs derived 
from constitutive Ehd1-null as compared to EHD1-WT mice were found to have a 
significant impairment of CSF-1R surface expression, CSF-1 induced CSF-1R 
signaling, and subsequent downstream CSF1-mediated macrophage functional 
effects. 
Due to the noticeable decrease in total levels of CSF-1R apparent on 
initial Western blots (Figure 3.7) after starvation of CSF-1 in EHD1-null BMDMs, I 
suspected the decreases in macrophage signaling and function might simply be 
due to less CSF-1R available to bind CSF-1 on the macrophage cell surface. All 
receptor tyrosine kinases (RTK) signaling begins with proper delivery and display 
of the receptor at the cell surface. If an RTK is not oriented properly at the cell 
surface, the receptor cannot bind ligand, be activated, signal, and produce 
downstream effects (20).  
A potential effect on macrophage development in constituative Ehd1-null 
mice due to defective cytokine signals and niche elements cannot be ruled out. 
Due to initial results using EHD1-null BMDMs from constitutively EHD1-deleted 
mice, I utilized EHD1-KO BMDMs to assure the effects observed were not due to 
abnormalities in bone marrow development. I conducted a series of experiments 
with inducible EHD1-KO compared to Control BMDMs to assess macrophage 
surface and total CSF-1R protein levels under conditions of CSF-1 removal from 
the culture media (CSF-1 deprivation). Analysis of surface and total levels of 
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CSF-1R protein under conditions of CSF-1 deprivation was performed using a 
combination of flow cytometry (Figures 3.8 and 3.21), Western blotting (Figure 
3.23), metabolic pulse-chase (Figure 3.26), and immunofluorescence imaging of 
non-permeabilized (Figure 3.22) or permeabilized BMDMs (Figures 3.24 and 
3.27). This combination of experiments demonstrated an overall reduction in 
CSF-1R levels when EHD1 was deleted and a clear impairment in the ability of 
newly synthesized CSF-1R to be transported to the cell surface.  
There are two possible mechanisms behind the change in macrophage 
biology I had observed (decreased total CSF-1R). When a cell has less total 
protein, either less of the protein is being made by the cell or the cell is degrading 
the protein at a higher rate. I excluded the possibility that the EHD1-KO BMDMs 
were making less of CSF-1R by conducting qRT-PCR and metabolic pulse-chase 
labeling of newly synthesized CSF-1R with [35S] (Figures 3.25 and 3.26).  
Previous studies have also shown that reduced surface expression of 
CSF-1R can result from defective glycosylation. Reduced surface CSF-1R 
expression resulting from defects in glycosylation of the receptor is seen upon 
expression of the HIV protein NEF, which inhibits glycosylation through 
incompletely understood mechanisms involving NEF activation of the SRC-family 
tyrosine kinase HCK as well as through HCK-independent mechanisms (70, 71). 
Naturally occurring loss-of-function mutations of CSF-1R have been identified in 
patients with hereditary diffuse leukoencephalopathy with spheroids (HDLS), and 
most of these mutations result in reduced CSF-1R protein expression (12). In 
both of the cases above, CSF-1R glycosylation in the Golgi is defective. In 
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contrast, metabolic pulse-chase studies showed that immature CSF-1R was fully 
converted into a mature form (fully glycosylated; higher molecular weight) in 
EHD1-KO BMDMs with essentially the same kinetics as in control cells (Figure 
3.26). CSF-1R mRNA expression is under the regulation of several transcription 
factors (19). However, transcriptional expression was unchanged. Similarly, a 
potential block in CSF-1R translational and subsequent maturation of the 
receptor (glycosylation) was excluded via metabolic pulse-chase analysis (Figure 
3.26). Thus, decreased CSF-1R production was ruled out as a potential 
mechanism for decreased CSF-1R signaling and macrophage function when 
EHD1 is absent from the cell. 
These findings clearly pointed to the possibility that post-synthetic 
transport of CSF-1R after its Golgi processing was defective in EHD1-KO 
BMDMs. Consistent with this idea, I observed that CSF-1R co-localizes with a 
cohort of CSF-1 in the Golgi compartment stained for GM130 (Golgi marker) 
(Figure 3.27). Our metabolic pulse-chase studies carried out in the presence of 
CSF-1 exposed the newly synthesized CSF-1R to its ligand, which promotes its 
rapid degradation (71). While this was clearly seen in control BMDMs, the mature 
band of CSF-1R remained intact for the duration of the experiment (Figure 3.26), 
supporting the conclusion that this cohort of CSF-1R did not reach the cell 
surface, consistent with our flow cytometry (Figure 3.8 and 3.21) and confocal 
imaging (Figure 3.22) analyses. When combined with the reduction in total CSF-
1R levels in EHD1-KO BMDMs, these results led to the idea that lack of EHD1 
allows CSF-1R traffic from the Golgi to a compartment where it is degraded.  
131 
 
Since other RTKs are degraded in lysosomes (20, 25) and a variety of 
receptors are known to traffic from the Golgi to the lysosome directly (72, 73), I 
considered the possibility that CSF-1R is alternatively sorted into the lysosome in 
EHD1-KO BMDMs where it is degraded. Our Western blotting analyses 
demonstrating that CSF-1R protein accumulates in EHD1-KO BMDMs when in 
the presence of Baf-A1 (Figure 3.28), together with confocal imaging of Baf-A1 
treated BMDMs (Figure 3.29), support this mechanism. It is of obvious interest to 
assess if the EHD1-dependent CSF-1R traffic pathway I describe is also 
important for other RTKs or represents a more restricted adaptation for CSF-1R. 
How the balance of these pathway operates and whether it is tunable during 
development, differentiation or functional responses of macrophage-lineage or 
other cells will be of considerable interest, especially in the context of human 
diseases in which inhibition of CSF-1R signaling would likely be desired (7, 13, 
16, 74). 
Although a novel role for EHD1 has been revealed in vitro, it will 
undoubtably be necessary further to investigate the physiological requirement of 
EHD1 for CSF1R-dependent generation of macrophage lineage cells in vivo. The 
question of whether or not EHD1 is essential to generate CSF1R signaling in vivo 
to help maintain monocyte-macrophage lineage under homeostasis and to help 
switch to monocyte-skewed hematopoiesis during immunological stress will need 
to be answered. In vivo analyses of tissue macrophages using an HSC-intrinsic 
inducible EHD1 deletion (chimeric mice utilizing Ehd1fl/fl; CreERT2 bone marrow) 
mouse model would be one way to answer these lingering questions directly. The 
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impact of EHD1 deletion in vivo on CSF-1R signaling needs to be verified to 
determine if the findings presented in this dissertation point to a physiologically 
relevant pathway of biological macrophage regulation. Using a chimeric 
approach with utilizing Ehd1fl/fl; CreERT2 bone marrow would allow selective EHD1 
deletion in hematopoietic lineages alone using a chimeric approach (Sieweke & 
Allen, 2013). Using tamoxifen treatment of live mice, the analysis could be done 
of peripheral blood (blood cell analyzer and blood smears) and spleens (FACS 
and immunohistochemistry) to changes in the development and function of the 
monocyte-macrophage lineage.  
A CSF-1R specific inducible system could also be of great value when 
assessing the role of EHD1 in CSF-1R signaling in vivo. Tamoxifen-inducible 
deletion via a CSF-1R specific deletion is currently available through Jackson 
Laboratories. However, the background of the CSF-1R inducible Cre mouse is 
FVB. Since Ehd1fl/fl mice are predominantly C57BL/6 background (Bhattacharyya 
et al., 2016; Rainey et al., 2010), the appropriate backcrosses would take an 
inconvenient amount of time. In contrast, the bone marrow chimeric model 
proposed previously could be carried out with existing mouse models. 
Targeting of CSF-1R signaling as a treatment of disease has made its way 
into clinical trials and has thus far been conducted regarding either inhibiting the 
receptor after activation or blocking receptor activation by using via an antibody 
that binds CSF-1R and inhibits CSF-1 binding (68). The decreased surface 
expression resulting from EHD1 deletion suggested a new target enabling the 
result of blocking CSF-1R signaling. Further studies will be conducted in order to 
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elucidate the mechanism of EHD1 further in the transport of CSF-1R to the 
macrophage cell surface due to the number of cells in the human body which 
express EHD1. Due to potential off-target effects, EHD1 alone is not a viable 
target of CSF-1R signaling inhibition. However, the possibility of blocking CSF-
1R transport to the macrophage cell surface is an attractive possible target. This 
project encourages the pursuit of further studies aimed at understanding of the 
mechanisms governing receptor tyrosine kinase presentation. 
Conclusion 
In conclusion, my findings show that exit of fully glycosylated, mature, 
CSF-1R from the Golgi is a regulated process under the control of two competing 
sorting procedures: a dominant EHD1-dependent pathway to facilitate its traffic to 
the cell surface and an alternate pathway to lysosomes for degradation. My 
findings support the conclusion that EHD1-dependent CSF1R transport, from the 
Golgi to the cell surface, are of key significance in determining the ultimate level 
of CSF-1R signaling (Figures 3.7 and 3.18) and downstream biological 
responses (Figures 3.3-3.6; 3.13-3.17). Collectively, the data from this study 
reveals a novel function for EHD1 in the exit of unstimulated CSF-1R from the 
Golgi apparatus to the macrophage cell surface for physiological activation of the 
receptor (Figure 4.1). 
The stage has been set for more in-depth studies of EHD proteins in other 
macrophage functions such as antigen presentation through MHC class I and 
MHC class II, processing of pathogens/antigens, and macrophage-assisted 
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pathologies. These findings will also serve as a basis for future studies aimed at 
uncovering the importance of the EHD proteins in trafficking of receptors on the 


















Figure 4.1. Working model of the novel EHD1 function in CSF-1R delivery 






Figure 4.1. Working model of the EHD1 function in CSF-1R delivery and 
display on the macrophage cell surface. EHD1-dependent post-Golgi sorting 
of newly synthesized CSF-1R in BMDMs directs the receptor towards the cell 
surface and away from the lysosome. In EHD1-expressing BMDMs, the surface 
delivery dominates. In the absence of EHD1, the lysosomal delivery is dominant, 
resulting in lower surface CSF-1R and reduced CSF1R-dependent cellular 
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